The cholinergic paradox: a new model for cognitive decline in Alzheimer’s and Down syndrome
A study in mouse models of Alzheimer’s disease and Down syndrome challenges the long-held view that cholinergic signaling is uniformly deficient. Researchers found that early cognitive impairment is driven by cholinergic hyperactivity, which can be corrected with anticholinergic drugs. In contrast, late-stage disease is characterized by cholinergic degeneration, where enhancing signaling with drugs like donepezil becomes beneficial. This reveals a functional shift in the cholinergic system over the course of disease progression.
Why it might matter to you:
This research refines a core hypothesis in neurodegeneration, suggesting that therapeutic timing is critical. For a researcher in neurodevelopmental disorders, it highlights the importance of understanding the dynamic, stage-specific neurochemical changes that underlie cognitive phenotypes. It could inform more precise intervention strategies that target specific disease phases rather than applying a uniform treatment approach.
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
